ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0428

ANCA Positivity and ANCA Associated Vasculitis in Patients with Rheumatoid Arthritis

Courtney O'Brien, Veena Ranganath and Tannaz Kermani, University of California Los Angeles, Los Angeles, CA

Meeting: ACR Convergence 2021

Keywords: ANCA, ANCA associated vasculitis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Vasculitis – ANCA-Associated Poster (0414–0436)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) with rheumatoid arthritis (RA) has been reported rarely, and, studies have found ANCA positivity in RA. The objective of the study was to describe a cohort of patients with RA and AAV and to compare patients with RA+AAV to those with RA+ANCA positivity without AAV.

Methods: In this retrospective study, a cohort of patients with RA+ANCA positivity evaluated at an academic center were included. Data abstracted included demographics, seropositivity, ANCA specificity, clinical characteristics of RA, diagnosis of AAV and clinical features of AAV.

Results: The study included 77 patients, mean (±SD) age 60.2 (17.2) years, 78% female. ANCA serologies included perinuclear (p)-ANCA in 58%, cytoplasmic (c)-ANCA in 26%, myeloperoxidase (MPO) in 43% and proteinase 3 (PR3) in 26%. Twenty patients (26%) were p-ANCA/MPO positive, 3 patients (4%) c-ANCA/PR3 positive, 7 patients (9%) were p-ANCA/PR3 positive and 1 patient (1%) was c-ANCA/MPO positive.

Twenty-five patients (32%) had a diagnosis of AAV; 9 (36%) microscopic polyangiitis (MPA), 8 (32%) granulomatosis with polyangiitis (GPA), 1 (4%) eosinophilic granulomatosis with polangiitis (EGPA), 1 (4%) GPA versus rheumatoid vasculitis (peripheral ulcerative keratitis, scleritis, sudden hearing loss, MPO positive). In 6 patients (24%) diagnosis was unclassifiable (1 interstitial lung disease attributed to vasculitis, 3 cutaneous vasculitis with ulcerations, 1 case of multiple digital infarctions from vasculitis, 1 leukocytoclastic vasculitis). Diagnosis of RA preceded vasculitis in 92% cases, was concurrent in 4% and followed vasculitis in 4%. Clinical manifestations of AAV are in Table 1. Among patients with RA+ANCA positivity but no diagnosis of AAV, 1 patient had nasal septal perforation with polyposis, 1 patient had vasculitic rashes and neuropathy attributed to vasculitis from RA, 2 patients had retinal vasculitis.

A comparison of patients with RA+AAV, and, patients with RA+ANCA without AAV is in Table 2. A higher proportion of patients with ANCA positivity via indirect immunofluorescence (IIF) along with antibody specificity to MPO or PR3 had a clinical diagnosis of AAV. These findings remained significant even if the 6 patients with unclassifiable disease were excluded (data not shown).

Conclusion: AAV in RA included an even number of cases of GPA and MPA. The diagnosis of RA almost always preceded the diagnosis of AAV and renal involvement was the most commonly present manifestation of AAV. There was uncertainty regarding attribution of isolated cutaneous vasculitis to RA or AAV and 24% of this cohort diagnosed as AAV had isolated skin disease. Many patients without vasculitis had positive MPO or PR3 antibodies. The presence of ANCA via IIF with MPO or PR3, even if discordant, separated patients with RA+AAV from those without vasculitis highlighting the need for clinical vigilance in this subset of patients with RA. The immune mechanisms underlying this rare overlap need to be elucidated.


Disclosures: C. O'Brien, None; V. Ranganath, None; T. Kermani, None.

To cite this abstract in AMA style:

O'Brien C, Ranganath V, Kermani T. ANCA Positivity and ANCA Associated Vasculitis in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/anca-positivity-and-anca-associated-vasculitis-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anca-positivity-and-anca-associated-vasculitis-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology